Hypera Pharma is one of the largest and most diversified pharmaceutical companies in Brazil, with a relevant presence across all key segments of the pharmaceutical retail market and leadership positions in several categories. The Company combines scale, efficiency and a broad portfolio of brands, with a continued focus on innovation to support its sustainable growth.
Hypera Pharma is organized into five major business units:
Through its umbrella brand Mantecorp Farmasa, the Company operates across several medical specialties in the Primary Care segment, with a relevant presence in the main therapeutic classes. Its portfolio comprises prescription drugs that combine safety and broad recognition among healthcare professionals, covering areas such as pain, respiratory system, gastroenterology and vitamins. Key products include Addera D3, Nesina, Dramin, Alivium, Predsim, Lisador and Rinosoro.
Through the Mantecorp Skincare brand, the Company offers dermocosmetics recommended by dermatologists throughout Brazil, according to information from Close-Up International, with a relevant presence in different skincare routines and a focus on the treatment and prevention of dermatological conditions.
The Company also operates through complementary brands, such as Simple, with vegan and cruelty-free products, and Bioage, focused on professional aesthetic treatments.
The Company is the leader in the Brazilian over-the-counter (OTC) medicines market, with a portfolio of brands widely recognized by consumers. These include Benegrip, Engov, Estomazil, Epocler, Neosaldina, Buscopan, Coristina D and Doril, present in categories such as pain, flu, gastroenterology and well-being.
The Company also operates in the nutritionals, vitamin supplements and sweeteners segments, with brands such as Tamarine, Biotônico Fontoura and Zero-Cal, as well as other solutions focused on daily care and preventive health
The Company has a significant presence in the branded generics and generics market through Neo Química, a nationally recognized brand in the segment. With broad capillarity and presence in virtually all points of sale across the country, the brand is Top of Mind in generics and recognized for its accessibility and reliability.
In line with the Company’s Mission to promote access to healthcare, the portfolio includes medicines across several therapeutic classes, contributing to the increased availability of quality treatments at more accessible prices for the population.
Since 2021, the Company has operated in the non-retail channel, which comprises public and private hospitals and clinics and represents approximately 40% of the Brazilian pharmaceutical market. In this channel, Hypera Pharma sells a portfolio of medicines targeted at the hospital environment, with a focus on clinical routines.
The portfolio includes brands such as Bac-Sulfitrin, Buscopan and Dramin, as well as Hyfol (propofol), the first product developed by the Company exclusively for the institutional channel, and Hyblut, Hypera Pharma’s first biological medicine, indicated for the treatment of deep vein thrombosis and pulmonary embolism.
Hypera Pharma has a large-scale, low-cost operation centralized in the largest pharmaceutical operating complex in Latin America, located in Anápolis, in the state of Goiás. The Company currently has more than 10 thousand employees and has been listed on B3’s Novo Mercado segment since 2008, reinforcing its commitment to best practices in corporate governance and transparency.
With nationwide reach, the Company has a broad sales and distribution structure, ensuring the availability of its products throughout Brazil through direct service to retailers and through distributors and wholesalers.
Its industrial operation in Anápolis (GO) has more than 170 thousand m² of built area and approximately 5.5 thousand employees dedicated to industrial activities. This structure supports a large-scale, low-cost operation, with high production efficiency and integrated processes.
In São Paulo, the Company has an industrial structure of approximately 30 thousand m², which is being expanded to internalize the production of brands acquired in recent transactions.
The industrial complex provides diversified production capacity, with annual production exceeding 1.4 billion consumption units (CUs), including production capacity of approximately 875 million solid units and approximately 300 million units of liquids, creams, oils and lotions.
To support its innovation strategy and the continuous development of its portfolio, the Company maintains Hynova, a pharmaceutical research and development center created in 2017. Hynova brings together highly qualified professionals, including professionals with master’s and doctoral degrees, dedicated to the development of medicines, dermocosmetics and nutraceuticals, with a focus on technology, efficiency and value creation.
History
Hypera Pharma began its operations in December 2001 and, in its early years, established itself as one of Brazil’s leading consumer goods companies, operating in categories such as personal care, cleaning products and food until 2006. Starting in 2007, the Company entered the pharmaceutical sector with the acquisition of DM Indústria Farmacêutica, marking the beginning of a consistent cycle of expansion and consolidation in the healthcare market.
In the following years, this movement was reinforced by a series of strategic acquisitions that significantly expanded the Company’s portfolio and presence in Brazil, including Farmasa (2008), Neo Química (2009) and Mantecorp (2011), consolidating its brand platform and positioning across different therapeutic categories.
In 2012, the Company advanced its innovation strategy by establishing Bionovis S.A., a joint venture with other Brazilian laboratories focused on the development of pharmaceutical biotechnology. Starting in 2015, the Company began a new strategic cycle focused exclusively on the pharmaceutical sector, divesting non-strategic businesses by selling its Cosmetics operation to Coty in 2015 and, subsequently, its Disposable Products operation to Ontex, a transaction completed in 2017.
This repositioning was accompanied by the consolidation of a more integrated business model focused on healthcare, with the continuous strengthening of the Company’s portfolio and innovation capabilities. In 2020, the Company acquired the Buscopan and Buscofem brands from Boehringer Ingelheim, expanding its presence in one of the main over-the-counter medicine categories in Brazil.
In the same year, the Company structured Hypera Ventures, its corporate venture capital initiative, making its first investment in Simple, a digital-native dermocosmetics brand aligned with the clean beauty concept.
In 2021, the Company completed important acquisitions that reinforced its portfolio, including brands from Takeda, such as Neosaldina, Dramin, Nebacetin, Nesina and Alektos, and expanded its presence in dermocosmetics with the acquisition of Bioage, strengthening its position in the professional aesthetics and skincare market. In the same period, the Company launched the ihypera digital channel (www.ihypera.com.br), an initiative aimed at bringing the Company closer to consumers and generating insights into consumption habits.
In 2022, the Company continued its growth strategy with the acquisition of a portfolio of brands from Sanofi, including AAS, Naturetti, Cepacol, Buclina and Hidantal, expanding its presence in both OTC and prescription medicines.
Also in 2022, the Company entered into strategic agreements with Boehringer Ingelheim for the acquisition of the technology and know-how related to the production of scopolamine, the active ingredient in Buscopan, as well as the acquisition of the industrial plant in Itapecerica da Serra (SP), reinforcing supply security and the productive integration of one of its main franchises.
Starting in 2022, Hypera Pharma focused its efforts on integrating recently incorporated assets and capturing operational and commercial synergies, with a focus on simplifying processes, increasing efficiency and improving operating cash generation.
In 2025, Votorantim S.A., an investment holding company with more than 100 years of history and a focus on long-term investments, joined Hypera Pharma’s controlling shareholder group and the Company’s Board of Directors. This movement strengthened corporate governance and further qualified the strategic decision-making process, contributing to value creation for the Company and its shareholders.